Role of monoamine oxidases to oxidative modification of myocardial proteins in rats with alloxan diabetes
Open Access
- 30 August 2026
- journal article
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 46 (4) , 93-100
Abstract
Diabetes mellitus is associated with a high risk of developing coronary heart disease, cardiac autonomic neuropathy, and diabetic cardiomyopathy, all of which involve oxidative stress mediated by insulin deficiency. The contribution of monoamine oxidases (MAOs) to the development of diabetic cardiomyopathy is currently being intensively studied, and enzyme inhibitors are considered promising cardioprotective drugs for diabetes. However, the possible contribution of MAO-A and MAO-B to direct oxidative damage to proteins and lipids in the myocardium during prolonged hyperglycemia remains unclear. The aim of the study was to assess the role of MAOs in the development of oxidative damage to myocardial proteins in alloxan diabetes. Material and Methods. The study was performed on 54 mature Wistar rats of both sexes. Diabetes mellitus was modeled by intraperitoneal administration of alloxan monohydrate at a dose of 163 mg/kg. To assess the contribution of MAOs to the development of oxidative stress, the MAO-B inhibitor selegiline was administered subcutaneously at a dose of 5 mg/kg daily. On the fourteenth day after alloxan administration, biomaterial for research was obtained. Oxidative modification of proteins in myocardial homogenates was determined spectrophotometrically by reaction with 2,4-dinitrophenylhydrazine, levels of lipid peroxidation products ‒ by extraction-spectrophotometric methods, MAO activity ‒ spectrophotometrically. Results and discussions. Within fourteen days of alloxan administration, an increase in glycemia was observed, accompanied by activation of MAO-A and MAO-B, as well as the accumulation of free radical protein and lipid oxidation products in the myocardium. Administration of selegiline to animals receiving alloxan prevented the activation of MAOs and the accumulation of protein oxidative modification products. These results demonstrate the potential for a direct prooxidant effect of MAOs in the myocardium and support the potential of research aimed at developing approaches that utilize drugs that modulate MAO activity in diabetes.Keywords
This publication has 15 references indexed in Scilit:
- Oxidative Modification of Proteins: From Damage to Catalysis, Signaling, and BeyondAntioxidants & Redox Signaling, 2021
- Modification of a spectrophotometric method for assessment of monoamine oxidase activity with 2,4-dinitrophenylhydrazine as a derivatizing reagentAnalytical Biochemistry, 2021
- Possible involvement of PI3K/AKT/mTOR signaling pathway in the protective effect of selegiline (deprenyl) against memory impairment following ischemia reperfusion in ratNeuropeptides, 2019
- Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallateBiomedicine & Pharmacotherapy, 2019
- Monoamine oxidase-dependent endoplasmic reticulum-mitochondria dysfunction and mast cell degranulation lead to adverse cardiac remodeling in diabetesCell Death & Differentiation, 2018
- Emerging role of monoamine oxidase as a therapeutic target for cardiovascular diseaseCurrent Opinion in Pharmacology, 2017
- Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathyFree Radical Biology and Medicine, 2015
- Insulin resistance in brain alters dopamine turnover and causes behavioral disordersProceedings of the National Academy of Sciences, 2015
- Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human BrainNeuropsychopharmacology, 2014
- LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivationAnalytical Biochemistry, 2005